Dispatches from Vitafoods Europe 2014

Omega-3’s newest big fish reveals sector ambitions

Omega-3’s newest big fish reveals sector ambitions

Mid-last year the chief of Norwegian omega-3 player EPAX told us, “We are the last of the big omega-3 independents.” Soon after US agri-food company FMC had snapped it up for $350m. Here FMC Nutraceuticals general manager Daniel H. Rosenbaum talks through the ‘how’ and the ‘why’ of the move…and the ‘where’ it might lead.

“The opportunity to take a position in omega-3 – particularly a premium position – was really one that fit our growth ambitions quite well,” he said.

Rosenbaum discusses omega-3 formulation, regulation, science and more here and why it is looking to further invest in health and wellness.

The omega-3 sector has seen serious consolidation in recent years with acquisitions including Martek Biosciences (DSM, €830m), Ocean Nutrition Canada (DSM, €430m) and Pronova Biopharma (BASF, €690m).

Related News

Red Queen theory argues that despite inducing greater and more speedy responses from rivals, the most active and aggressive firms are the best performers.

Red Queen Rules: Understanding nutra space acquisition and evolution

FMC to split into two publicly traded companies

FMC to split into two publicly traded companies

FMC said its Seal Sands omega-3s production facility will start shipping products in the first quarter of 2014.

FMC posts earnings, says UK omega-3s facility nearing full scale production

Mike Smith: 'Our microcrystalline cellulose is already used by some of the biggest brands in supplements so we’re excited about being able to talk to them about omega-3s'

FMC: 'We looked at the omega-3 area broadly and it was clear Epax was the premier property in this space'

FMC seals $345m deal to buy omega-3 expert Epax

FMC Corporation makes bold move into omega-3 market with $345m deal to buy Epax

Epax chief Ola Snove: “We can move faster and have the capacity to be better partners than the giants. We are specialists – we only do omega-3.”

Epax chief: ‘We are the last of the big omega-3 independents’